The estimated Net Worth of Gary A. King is at least $4.07 million dollars as of 1 August 2019. Mr. King owns over 60,000 units of Myriad Genetics stock worth over $4,070,010 and over the last 14 years he sold MYGN stock worth over $0. In addition, he makes $0 as Executive Vice President - International Operations at Myriad Genetics.
Gary has made over 15 trades of the Myriad Genetics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of MYGN stock worth $1,423,800 on 1 August 2019.
The largest trade he's ever made was exercising 60,000 units of Myriad Genetics stock on 1 August 2019 worth over $1,423,800. On average, Gary trades about 8,004 units every 52 days since 2010. As of 1 August 2019 he still owns at least 154,871 units of Myriad Genetics stock.
You can see the complete history of Mr. King stock trades at the bottom of the page.
Gary A. King is the Executive Vice President - International Operations of Myriad Genetics, Inc. Mr. King has been employed in the life sciences industry for more than 25 years. From June 2008 to June 2010, he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company that develops novel biomarker diagnostics for critical diseases. From June 2002 to February 2008, he served as Vice President, International Operations at Biosite Incorporated, a developer of diagnostic products and antibody development technologies where he spent six years building and leading all of the company’s commercial activities outside the United States. Mr. King received his B.A. degree in Zoology from Pomona College and a M.B.A. degree from Stanford University.
Gary King is 63, he's been the Executive Vice President - International Operations of Myriad Genetics since 2010. There are 5 older and 20 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
Gary's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum et Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: